Galderma has initiated six new studies -- and the company is increasing its commitment to aesthetic research and innovation. 

Galderma will present data featuring its hyaluronic acid (HA) dermal filler, Restylane Lyft, at the American Society for Dermatologic Surgery (ASDS) annual meeting on  October 11-14 in Phoenix.

Restylane Lyft poster presentations will be showcased, including a Phase III study that supported the recent FDA approval of Restylane Lyft for the treatment of age-related volume loss in the hands.

"We are shaping the ever-evolving aesthetics industry like never before by developing new solutions to help drive consumers into aesthetic offices," said Alisa Lask, General Manager & Vice President of the U.S. Aesthetic Business at Galderma. 

The company's R&D expansion also includes a significant increase in the number of women selected as clinical investigators. Since Galderma acquired the U.S. rights to Dysport (abobotulinumtoxinA), Restylane, and Sculptra Aesthetic in 2014, the number of female clinical investigators in company-sponsored trials has more than doubled.

"We understand the vast majority of aesthetics consumers are women, so we have made a significant effort to increase the number of female investigators in our trials," said Xiaoming Lin, Global Head, Aesthetic Development at Galderma.

The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology™ products; two studies for Dysport evaluating patient satisfaction and duration; and one study focusing on the unique properties of Sculptra Aesthetic (injectable poly-L-lactic acid).

"I am excited to partner with a company like Galderma who is continuing to invest in the aesthetics market and being thoughtful about the composition of their clinical trial investigator group," said Sue Ellen Cox, MD, founder and medical director of Aesthetic Solutions, Chapel Hill, NC and a primary investigator for Galderma's new trials.